Ajuts a la recerca

Breast Cancer Research Program- Breakthrough Award

Organisme

Defense Health Program- Department of Defense -Congressionally Directed Medical Research Programs- Breast Cancer Research Program
Breakthrough Award
Funding Opportunity Number: W81XWH-13-BCRP-BREAKTHROUGH2
Catalog of Federal Domestic Assistance Number: 12.420

The BCRP challenges the scientific community to design research that will address the urgency of ending breast cancer.

Specifically, the BCRP seeks to accelerate high-impact research with clinical relevance, encourage innovation and stimulate creativity, facilitate multidisciplinary collaborations, and support future breast cancer leaders.

Objecte

a. Topics: Considering the BCRP's vision to end breast cancer, each application must address at least one of the following overarching challenges:

1. Eliminate the mortality associated with metastatic breast cancer

2. Prevent breast cancer (primary prevention)

3. Distinguish aggressive breast cancer from indolent cancers; overcome the problems of overdiagnosis and overtreatment

4. Revolutionize treatment regimens by replacing drugs that have life-threatening toxicities with safe, effective interventions

5. Identify what drives breast cancer growth and metastasis; identify why some breast cancers become life-threatening metastases

6. Identify what makes the breast susceptible to cancer development

7.Determine why some, but not all, women get breast cancer

8.Determine why/how breast cancer cells lay dormant for years and then re-emerge (recurrence); determine how to el iminate dormant cells early

b. Funding Levels: The following are general descriptions, although not all-inclusive, of the scope of research projects that would be appropriate to propose under each funding level:

1. Funding Level 1: Innovative, high-risk/high-reward research that is in the earliest stages of idea development. Research with potential to yield new avenues of investigation. Proof of concept. No preliminary data required.

2. Funding Level 2: Research that is already supported by preliminary data and has potential to make significant advancements toward translation from the laboratory to the clinic. Demonstration of efficacy in in vivo models or clinical research studies, as applicable.

c. Budget and duration: Applications with a single PI or Partnering PI Option have the same funding limits:

1. Funding Level 1: The maximum period of performance is 3 years. The maximum allowable direct costs for the entire period of performance are $350,000 plus indirect costs.

2. Funding Level 2: The maximum period of performance is 3 years. The maximum allowable direct costs for the entire period of performance are $700,000 plus indirect costs.
 

Termini oficial

Pre-Application Submission Deadline: 5:00 p.m. Eastern time (ET), October 8, 2013
Invitation to Submit an Application: November 2013
Application Submission Deadline: 11:59 p.m. ET, January 15, 2014
Peer Review: March 2014
Programmatic Review: May 2014

Termini IISPV

Cal comunicar abans del 15 de setembre de 2013 que es vol participar a la convocatòria, enviant un e-mail a europa@iispv.cat . Termini: 2 d’octubre de 2013. L'IISPV gestiona les ajudes dels seus investigadors, no és l'entitat convocant.

Pujar